Background
A wide variety of diseases are associated with splenomegaly, or enlargement of the spleen, with many of the mechanisms leading to this condition being exaggerated forms of normal spleen function. (See Etiology.)
The spleen is a functionally diverse organ with active roles in immunosurveillance and hematopoiesis. It lies within the left upper quadrant of the peritoneal cavity and abuts ribs 9-12, the stomach, the left kidney, the splenic flexure of the colon, and the tail of the pancreas. A normal spleen weighs 150 g and is approximately 11 cm in craniocaudal length.[1]
The normal spleen is usually not palpable, although it can sometimes be palpated in adolescents and individuals with a slender build. However, an enlarged or palpable spleen is not necessarily of clinical significance. Moreover, certain individuals with broadly splayed costal margins have readily palpable, but small, spleens. (See Presentation.)
Spleens weighing 400-500 g indicate splenomegaly, and some authors consider spleens weighing more than 1000 g to indicate massive splenomegaly. Spleens that are prominent below the costal margin typically weigh 750-1000 g. Poulin et al defined splenomegaly as moderate if the largest dimension is 11-20 cm, and severe if the largest dimension is greater than 20 cm. (See Treatment and Workup.)
In many instances, the spleen enlarges as it performs its normal functions. The 4 most important normal functions of the spleen are as follows:
- Clearance of microorganisms and particulate antigens from the blood stream
- Synthesis of immunoglobulin G (IgG), properdin (an essential component of the alternate pathway of complement activation), and tuftsin (an immunostimulatory tetrapeptide)
- Removal of abnormal red blood cells (RBCs)
- Embryonic hematopoiesis in certain diseases
Etiology
As previously mentioned, many of the mechanisms leading to an enlarged spleen are exaggerated forms of normal spleen function. Although a wide variety of diseases are associated with enlargement of the spleen, the following 6 etiologies of splenomegaly are considered primary:
- Immune response work hypertrophy - Such as in subacute bacterial endocarditis or infectious mononucleosis
- RBC destruction work hypertrophy - Such as in hereditary spherocytosis or thalassemia major
- Congestive - Such as in splenic vein thrombosis or portal hypertension
- Myeloproliferative - Such as in chronic myeloid metaplasia
- Infiltrative - Such as in sarcoidosis and some neoplasms
- Neoplastic - Such as in chronic lymphocytic leukemia and the lymphomas
Miscellaneous causes of splenomegaly include trauma, cysts, hemangiomas, metastasis, giant abscess (see the images below), and certain drugs (eg, RhoGAM).
This patient has a splenic abscess due to pneumococcal bacteremia. Note that the massively enlarged spleen is readily visible, with minimal retraction in the left upper quadrant.
Resected specimen from the patient in the previous image. Note the discrete abscesses adjacent to normal parenchyma. Inflammatory splenomegaly
This is an acute enlargement of the spleen that develops in association with various infections or inflammatory processes and results from an increase in the defense activities of the organ. The demand for increased antigen clearance from the blood may lead to increased numbers of reticuloendothelial cells in the spleen and stimulate accelerated antibody production, with resultant lymphoid hyperplasia. Examples include splenomegaly from lupus and Felty syndrome, and from viral infections such as Ebstein Barr Virus–induced mononucleosis.
Hyperplastic splenomegaly
In this setting, splenomegaly is thought to reflect work hypertrophy that results from the removal of abnormal blood cells from the circulation (either cells with intrinsic defects or cells coated with antibody) or, in some cases, that results from extramedullary hematopoiesis (ie, myeloproliferative disease).[2]
Congestive splenomegaly
This condition develops as a result of cirrhosis with portal hypertension, splenic vein occlusion (thrombosis), or congestive heart failure (CHF) with increased venous pressure.
Infiltrative splenomegaly
In this setting, splenomegaly is the result of engorgement of macrophages with indigestible materials (eg, sarcoidosis, Gaucher disease, amyloidosis, metastatic malignancy).
Infectious splenomegaly
Splenic filtering of blood-borne pathogens, especially encapsulated organisms, may lead to abscess formation. Because many splenic abscesses may be indolent in presentation, splenic size may be increased as the abscess enlarges. This is a relatively uncommon, but important, process to recognize and treat.
Epidemiology
In the United States, one large series reported a palpable spleen in 2% of patients, and another, in 5.6% of patients. Tropical splenomegaly syndrome has the highest predilection for indigenous persons of and visitors to the malarial belt of tropical Africa.
Race-related demographics
No race predilection is recognized for splenomegaly. However, note that blacks may have hemoglobin SC disease, a disorder related to sickle cell disease. Unlike sickle cell disease that results in a small, autoinfarcted spleen, patients with hemoglobin SC disease may have splenomegaly that accompanies their pigment gallstones.
Sex-related demographics
Tropical splenomegaly syndrome (or hyperactive malarial syndrome) has a female-to-male incidence ratio of 2:1. Otherwise, no sex predilection is documented for splenomegaly.
Age-related demographics
No age predilection is recognized for splenomegaly. Nonetheless, the capsules of older spleens are much thinner than their younger counterparts. The combination of capsular thinning with increased spleen weight and size makes splenic injury more common in elderly persons. These factors account for the increased likelihood of splenectomy for trauma in this subgroup.
Prognosis
The prognosis for patients with splenomegaly is usually excellent and not substantially different from age-matched controls, but it is impacted by the underlying disease state rather than the presence of splenomegaly or the postsplenectomy state.
Morbidity and mortality
Morbidity and mortality in cases of splenomegaly principally stem from associated disease states or surgical procedures, rather than from the splenomegaly itself. The rates for morbidity and mortality are highly variable and relate to the presence or absence of comorbidities, hemorrhage, and organ failure.
Patients with enlarged spleens are more likely to have splenic rupture from blunt abdominal or low thoracic trauma. These patients are unlikely to undergo nonoperative management of their splenic injury or splenic salvage maneuvers, because their spleen is abnormal with regard to architecture, capsule tensile strength, and, commonly, hemostatic function.
Patient Education
Patients with splenomegaly need education with regard to decreasing their risk of splenic hemorrhage. These patients must be cautioned about contact sports and other activities that may acutely increase intra-abdominal pressure or place excessive forces on the left upper quadrant, left flank, or lateral back. This decreases the likelihood of splenic rupture in a patient with an abnormal splenic mass and capsule. The routine use of seat belts is essential while driving or riding in a motor vehicle.
Additional education regarding the signs and symptoms of postsplenectomy sepsis cannot be overstressed. Prompt antibiotic therapy may be lifesaving.
Education represents a mandatory strategy in the prevention of overwhelming postsplenectomy infection (OPSI). Asplenic patients should be encouraged to wear a Medi-Alert (Pinellas Park, Fla/Henderson, Nev) bracelet and carry a wallet card explaining their lack of a spleen. Patients should also be aware of the need to notify their physician in the event of an acute febrile illness, especially if it is associated with rigors or systemic symptoms.
For patient education information, see the Infections Center, as well as Mononucleosis (Mono).
Eichner ER. Splenic function: normal, too much and too little. Am J Med. Feb 1979;66(2):311-20. [Medline].
Ginzel AW, Kransdorf MJ, Peterson JJ, Garner HW, Murphey MD. Mass-like extramedullary hematopoiesis: imaging features. Skeletal Radiol. Nov 20 2011;[Medline].
Butler JR, Eckert GJ, Zyromski NJ, Leonardi MJ, Lillemoe KD, Howard TJ. Natural history of pancreatitis-induced splenic vein thrombosis: a systematic review and meta-analysis of its incidence and rate of gastrointestinal bleeding. HPB (Oxford). Dec 2011;13(12):839-45. [Medline]. [Full Text].
Zhu JH, Wang YD, Ye ZY, Zhao T, Zhu YW, Xie ZJ, et al. Laparoscopic versus open splenectomy for hypersplenism secondary to liver cirrhosis. Surg Laparosc Endosc Percutan Tech. Jun 2009;19(3):258-62. [Medline].
Anegawa G, Kawanaka H, Uehara H, Akahoshi T, Konishi K, Yoshida D, et al. Effect of laparoscopic splenectomy on portal hypertensive gastropathy in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol. Sep 2009;24(9):1554-8. [Medline].
Bezerra AS, D'Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement?. AJR Am J Roentgenol. May 2005;184(5):1510-3. [Medline]. [Full Text].
Goldstone J. Splenectomy for massive splenomegaly. Am J Surg. Mar 1978;135(3):385-8. [Medline].
Laws HL, Burlingame MW, Carpenter JT, Prchal JT, Conrad ME. Splenectomy for hematologic disease. Surg Gynecol Obstet. Oct 1979;149(4):509-12. [Medline].
Musser G, Lazar G, Hocking W, Busuttil RW. Splenectomy for hematologic disease. The UCLA experience with 306 patients. Ann Surg. Jul 1984;200(1):40-5. [Medline]. [Full Text].
Wilhelm MC, Jones RE, McGehee R, et al. Splenectomy in hematologic disorders. The ever-changing indications. Ann Surg. May 1988;207(5):581-9. [Medline]. [Full Text].
Flowers JL, Lefor AT, Steers J, et al. Laparoscopic splenectomy in patients with hematologic diseases. Ann Surg. Jul 1996;224(1):19-28. [Medline]. [Full Text].
Wang KX, Hu SY, Zhang GY, Chen B, Zhang HF. Hand-assisted laparoscopic splenectomy for splenomegaly: a comparative study with conventional laparoscopic splenectomy. Chin Med J (Engl). Jan 5 2007;120(1):41-5. [Medline]. [Full Text].
Subhasis RC, Rajiv C, Kumar SA, Kumar AV, Kumar PA. Surgical treatment of massive splenomegaly and severe hypersplenism secondary to extrahepatic portal venous obstruction in children. Surg Today. 2007;37(1):19-23. [Medline].
Poulin EC, Mamazza J, Schlachta CM. Splenic artery embolization before laparoscopic splenectomy. An update. Surg Endosc. Jun 1998;12(6):870-5. [Medline].
Kawanaka H, Akahoshi T, Kinjo N, et al. Technical standardization of laparoscopic splenectomy harmonized with hand-assisted laparoscopic surgery for patients with liver cirrhosis and hypersplenism. J Hepatobiliary Pancreat Surg. 2009;16(6):749-57. [Medline].
Xu WL, Li SL, Wang Y, Shi BJ, Li M, Li YC, et al. Laparoscopic splenectomy: color Doppler flow imaging for preoperative evaluation. Chin Med J (Engl). May 20 2009;122(10):1203-8. [Medline].
Shaw JH, Print CG. Postsplenectomy sepsis. Br J Surg. Oct 1989;76(10):1074-81. [Medline].

